Efficacy of pegylated interferon plus ribavirin treatment in HIV/ hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 6, 2008, Pages 1365-1373

  Mira, José A ^a   López Cortés, Luis F ^b   Barreiro, Pablo ^c   Tural, Cristina ^d   Torres Tortosa, Manuel ^e   de los Santos Gil, Ignacio ^f   Martín Rico, Patricia ^g   Ríos Villegas, María J ^h   Hernández Burruezo, José Juan ⁱ   Merino, Dolores ^j   López Ruz, Miguel Ángel ^k   Rivero, Antonio ^l   Muñoz, Leopoldo ^m   González Serrano, Mercedes ⁿ   Collado, Antonio ^o   Macías, Juan ^a   Viciana, Pompeyo ^b   Soriano, Vincent ^c   Pineda, Juan A ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e Hospital Punta Europa   (Spain)

^f HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^g HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

ⁱ Unidad de Enfermedades Infecciosas   (Spain)

^j HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

^k HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^l HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^m HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

ⁿ HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^o HOSPITAL TORRECÁRDENAS   (Spain)

more..

Author keywords

Antiretroviral therapy; HCV genotype; Sustained virological response

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; AMPRENAVIR PHOSPHATE PLUS RITONAVIR; ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR PLUS RITONAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR PLUS EMTRICITABINE; TENOFOVIR PLUS LAMIVUDINE; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS TYPING;

ADENINE; ADULT; ANTI-HIV AGENTS; BLOOD; COHORT STUDIES; DEOXYCYTIDINE; DIDEOXYNUCLEOSIDES; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON ALFA-2B; LAMIVUDINE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHOSPHONIC ACIDS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 56649124849     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn420     Document Type: Article

References (26)

1. Torriani FJ, Rodríguez-Torres M, Rockstroh JK et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-50.
2. Carrat F, Bani-Sadr F, Pol S et al. Pegylated interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients. A randomized controlled trial. JAMA 2004; 292: 2839-48.
3. Chung RT, Andersen J, Volberding P et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351 451-9.
4. Laguno M, Murillas J, Blanco JL et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18: F27-36.
5. Mira JA, Torre-Cisneros J, Merino D et al. Efficacy of pegylated interferon plus ribavirin in HIV/HCV co-infection outside of well-circumscribed clinical trials: The Andalusian multicenter study. In: Abstracts of the Thirteenth Conference on Retroviruses and Opportunisyic Infections, Denver, USA, 2006. Abstract 861. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
6. Manns P, McHutchinson JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment ot chronic hepatitis C: A randomized trial. Lancet 2001; 358: 958-65.
7. Fried, MW, Shiffamn ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
8. Hadziyannis SJ, Sette H, Morgan TR et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
9. Bani-Sadr F, Carrat F, Pol S et al. Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy. J Acquir Immune Defic Syndr 2005; 40: 47-52.
10. Soriano V, Puoti M, Sulkowski M et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from HCV-HIV International Panel. AIDS 2007; 21: 1073-89.
11. Mauss S. Treatment of viral hepatitis in HIV-coinfected patients - adverse events and their management. J Hepatol 2006; 44 Suppl 1: S114-8.
12. Bani-Sadr F, Denoeud L, Morand P et al. Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: Does abacavir play a role? J Acquir Immune Defic Syndr 2007; 45: 123-5.
13. Pineda JA, Mira JA, de los Santos Gil I et al. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/ HIV-coinfected patients. J Antimicrob Chemother 2007; 60: 1347-54.
14. Vispo E, Barreiro P, Pineda JA et al. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther 2008; 13: 429-37.
15. Mira JA, López-Cortés LF, Merino D et al. Predictors of severe hematological toxicity secondary to pegylated interferon plus ribavirin in HIV/HCV-coinfected patients. Antivir Ther 2007; 12 1225-35.
16. Scheuer PJ. Classification of chronic viral hepatitis: A need for reassessment. J Hepatol 1991; 13: 372-4.
17. Moreno A, Quereda C, Muriel A et al. Does the choice of NRTI have a significant influence on the outcome of peg-IFN plus ribavirin among HIV/HCV-coinfected patients? In: Abstracts of the Fifteenth Conference on Retroviruses and Opportunistic Infections, Boston, USA, 2008. Abstract 1075. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
18. González-García J, Berenguer J, Condes E et al. The use of tenofovir plus lamivudine/emtricitabine is associated with an improved response to pegylated interferon plus ribavirin in HIV/HCV-co-infected patients receiving HAART: The Gesida 50/06 study. In: Abstracts of the Fifteenth Conference on Retroviruses and Opportunistic Infections, Boston, USA, 2008. Abstract 1076. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
19. Nuñez M, Miralles C, Berdún MA et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: The PRESCO trial. AIDS Res Hum Retoviruses 2007; 23: 972-82.
20. Faletto M, Miller W, Garvey E et al. Unique intracellular activation of the potent anti-HIV agent 1592U89. Antimicrob Agents Chemother 1997; 41: 1099-107.
21. Wu J, Larson G, Walker H et al. Phosphorylation of ribavirin and viramidine by adenosine kinase and cytosolic 5′-nucleotidase II: implications for ribavirin metabolism in erythrocytes. Antimicrob Agents Chemother 2005; 49: 2164-71.
22. Dore GJ, Torriani FJ, Rodriguez-Torres M et al. Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection. AIDS 2007; 21: 1555-9.
23. Gopal K, Johnson TC, Gopal S et al. Correlation between β-lipoprotein levels and outcome of hepatitis C treatment. Hepatology 2006; 44: 335-40.
24. Akuta N, Suzuki F, Kawamura Y et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: Amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007; 46: 403-10.
25. Del Valle J, Mira JA, de los Santos I et al. Baseline serum low-density lipoprotein cholesterol levels predict response to HCV therapy in HIV/HCV-coinfected patients. AIDS 2008; 22: 923-30.
26. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology 2002; 36 Suppl 1: S65-73.